MEDIPOST acquires the Japanese patent in hair loss prevention and hair growth promoting composition2018/07/04STEM CELL THERAPEUTIC
MEDIPOST acquires patents on the “Mesenchymal Stem Cell Culture Method” in 6 European countries2018/06/27STEM CELL THERAPEUTIC
Significant increase in the revenue of MEDIPOST stem cell therapeutics CARTISTEM in comparison to the previous year2018/04/20STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Stem Cell Culture Medium Technique for Hair Loss Treatment2018/02/28STEM CELL THERAPEUTIC
MEDIPOST’s Alzheimer’s Disease Drug Approved by FDA for Clinical Trials2018/02/05STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for its ‘CARTISTEM’ Production Technology’ in Six European Countries2017/12/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Core Alzheimer’s Disease Treatment Technology in Six European Countries2017/10/25STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for Commercializing High-efficiency Technology to Culture Stem Cell2017/09/13STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its Stem Cell-based Alzheimer’s Disease Treatment Composition2017/06/28STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent for its High-Efficient Technology for Culturing Stem Cells2017/06/14STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in UK for its Alzheimer’s Disease Treatment Technique that Uses Stem Cells2017/05/17STEM CELL THERAPEUTIC
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
